Immunostimulatory agents such as recombinant cytokines (INF-α, IL-2) used in the treatment of cancer have adverse consequences, including the acute phase response, cell and tissue abnormalities/injury, cytokine release/cytokine storm, tumor lysis syndrome, vascular leak, and autoimmunity [80]. Here, IFNA17 is linked to cancer.